News for Aclaris Therapeutics, Inc. (ACRS)

Market Analysis by covering: Summit Therapeutics PLC, TherapeuticsMD Inc, Viking Therapeutics Inc, Aclaris Therapeutics Inc. Read 's Market Analysis on Investing.com

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Following the recent release of its first-quarter results, Aclaris Therapeutics (ACRS) has experienced a revision in its stock price target. Analyst Raghuram Se

Scotiabank's analyst, Louise Chen, has revised the price target for Aclaris Therapeutics (ACRS) from $15 to $9 while maintaining an Outperform rating. This adju

**media[620227]**

Aclaris Therapeutics (ACRS) reports Q1 GAAP EPS of -$0.12 and revenue of $1.46M (-39.2% Y/Y). Cash reserves expected to fund operations through H1 2028.

Aclaris Therapeutics (ACRS) has named Jesse Hall, M.D. as its new Chief Medical Officer. Dr. Hall brings a wealth of expertise in medical and clinical developme

**media[601437]**

WAYNE, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. ( ACRS), a clinical-stage biopharmaceutical company focused on developing novel prod

Aclaris (ACRS) delivered earnings and revenue surprises of 68.75% and 313.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $9.2 million for Q4 2024, exceeding the estimated $2.11 million.Net Loss: $96.6 million for Q4 2024, a significant increase from $1.5 million in Q4 20

**media[552096]**

- Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data from CTTQ's Phase 2 Studies of Bo

- Data Generated to Date Support Potential for Aclaris' ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE)

WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. ( ACRS) (the ”œCompany” or ”œAclaris”), a clinical-stage biopharmaceutical comp

Burning Rock Biotech (BNR) experienced a significant stock drop of 5.02%, with shares priced at $6.25 and a trading volume of 4,410 shares. The stock's turnover

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

WAYNE, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. ( ACRS)(the ”œCompany” or ”œAclaris”), a clinical-stage biopharmaceutical compa

**media[482652]**